NCT lookup

Key Inclusion Criteria:

1. Diagnosis of AD according to the American Academy of Dermatology consensus criteria (Eichenfield 2003) at screening visit
2. Chronic AD diagnosed at least 1 year prior to the screening visit
3. IGA = 4 at screening and baseline visits
4. EASI ≥21 at the screening and baseline visits
5. BSA ≥15% at screening and baseline visits
6. Documented recent history (within 6 months before the baseline visit) of inadequate response to topical AD medication(s)
7. At least 11 (of a total of 14) applications of a stable dose of topical emollient (moisturizer) twice daily during the 7 consecutive days immediately before the baseline visit

Key Exclusion Criteria:

1. Participation in a prior dupilumab clinical study
2. Treatment with a systemic investigational drug before the baseline visit
3. Treatment with a topical investigational drug within 2 weeks prior to the baseline visit
4. Treatment with crisabarole within 2 weeks prior to the baseline visit
5. History of important side effects of medium potency topical corticosteroids (e.g, intolerance to treatment, hypersensitivity reactions, significant skin atrophy, systemic effects), as assessed by the investigator or patient's treating physician
6. Treatment with a topical calcineurin inhibitor (TCI) within 2 weeks prior to the baseline visit
7. Having used any of the following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, is likely to require such treatment(s) during the first 4 weeks of study treatment:

   1. Immunosuppressive/immunomodulating drugs (e.g, systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon gamma, Janus kinase inhibitors, azathioprine, methotrexate, etc.)
   2. Phototherapy for AD
8. Treatment with biologics, as follows:

   1. Any cell-depleting agents including but not limited to rituximab:

      within 6 months before the baseline visit, or until lymphocyte and CD 19+ lymphocyte count returns to normal, whichever is longer
   2. Other biologics: within 5 half-lives (if known) or 16 weeks before the baseline visit, whichever is longer
9. Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit
10. Body weight \<15 kg at baseline

Note: Other Inclusion/ Exclusion criteria apply

• Birmingham, Alabama, United States
• Gilbert, Arizona, United States
• Bakersfield, California, United States
• Long Beach, California, United States
• Mission Viejo, California, United States
• Rolling Hills Estates, California, United States
• San Diego, California, United States
• Denver, Colorado, United States
• Coral Gables, Florida, United States
• Tampa, Florida, United States
• Tampa, Florida, United States
• Macon, Georgia, United States
• Sandy Springs, Georgia, United States
• Chicago, Illinois, United States
• Normal, Illinois, United States
• Rockville, Maryland, United States
• Ypsilanti, Michigan, United States
• Minneapolis, Minnesota, United States
• St Louis, Missouri, United States
• Forest Hills, New York, United States
• New York, New York, United States
• Rochester, New York, United States
• Gahanna, Ohio, United States
• Portland, Oregon, United States
• Philadelphia, Pennsylvania, United States
• Charleston, South Carolina, United States
• North Charleston, South Carolina, United States
• Bellaire, Texas, United States
• San Antonio, Texas, United States
• Norfolk, Virginia, United States
• + 31 more on CT.gov